Peptide deformylase inhibitor containing 4-methylene pyrrolidine

Abstract

The invention provides a peptide deformylase inhibitor containing 4-methylene pyrrolidine and relates to a peptide deformylase inhibitor. The peptide deformylase inhibitor has the structural formula shown in the specification, and in the formula, R1 is alkyl, R2 is H or alkyl, and R3 is alkyl or aryl or heterocycle. The peptide deformylase inhibitor can inhibit bacterial to synthesize protein so as to kill the bacterial, has small chance of drug resistance generation, is safe for a human body and can kill strains having antibiotic resistance, such as methicillin-resistant staphylococcus aureus (MRSA) and penicillin resistant streptococcus pneumoniae (PRSP).

Description

technical field [0001] A peptide deformylase inhibitor containing 4-methylenepyrrolidine relates to a peptide deformylase (PDF) inhibitor. The invention belongs to the technical field of antibiotics and antibacterial drugs. Background technique [0002] Antibiotics refer to microbial products (secondary metabolites) that can kill or inhibit some specific microorganisms such as bacteria, fungi, rickettsia, mycoplasma, chlamydia and viruses at high dilution. In 1929, British scholar Fleming first discovered penicillin among antibiotics. In 1940, based on Fleming's discovery, Florey and Chain invented penicillin for human injection. In 1944, Waksman isolated streptomycin. What is exciting is that this antibiotic has a strong resistance to Mycobacterium tuberculosis, making tuberculosis no longer a terminal disease. Since then, chloramphenicol (1947), neomycin (1949), oxytetracycline (1950), erythromycin (1952), tetracycline (1953) and semi-synthetic drugs that appeared after...

AI Technical Summary

Problems solved by technology

As far as the current research situation is concerned, the chance of bacterial resistance to PDF inhibitors is very small

Images